| Literature DB >> 23496969 |
Ester Mm Klaassen1, Brenda Ejt Thönissen, Guillaume van Eys, Edward Dompeling, Quirijn Jöbsis.
Abstract
The aetiology of childhood asthma is complex. An early dysfunction in the immunological development of the innate immune system in combination with environmental factors possibly triggers asthma. CD14 and toll-like receptors are important components of the innate immune system. The aim of this systematic review was to obtain a better insight into the relation between CD14 and toll-like receptors and childhood asthma in Caucasians. We searched PubMed and EMBASE for relevant articles. In total, 44 articles were included. The quality of the selected studies was independently assessed by the first two authors using the Newcastle-Ottawa quality assessment scale. Toll-like receptor 2, toll-like receptor 6, toll-like receptor 9, and toll-like receptor 10 appear to have some association with childhood asthma in Caucasians. The evidence for a relation of CD14 with childhood asthma is limited. In conclusion, there is no convincing evidence yet for a role of CD14 and toll-like receptors in relation to childhood asthma. Future studies should include haplotype analysis and take environmental factors into account to further clarify the role of CD14 and toll-like receptors on childhood asthma.Entities:
Year: 2013 PMID: 23496969 PMCID: PMC3602113 DOI: 10.1186/1710-1492-9-10
Source DB: PubMed Journal: Allergy Asthma Clin Immunol ISSN: 1710-1484 Impact factor: 3.406
Figure 1PRISMA flow diagram of search. The flow diagram depicts the flow of information through the different phases of the systematic review. It maps out the number of records identified, included and excluded, and the reasons for exclusions.
Quality scoring based on the Newcastle-Ottawa quality assessment scale: cohort studies
| Bieli † [ | 2007 | * | * | * | - | * | * | - | * | - | +/− |
| Bottema [ | 2010 | * | * | NA | * | - | - | - | * | - | +/− |
| Custovic [ | 2011 | * | * | - | * | * | * | - | * | * | + |
| Eder † [ | 2004 | * | * | * | - | * | * | - | * | - | +/− |
| Ege † [ | 2007 | * | * | * | - | * | * | - | * | - | +/− |
| Fageras Bottcher † [ | 2004 | - | * | * | - | * | * | * | * | - | +/− |
| Guerra [ | 2004 | * | * | - | * | * | * | - | - | - | +/− |
| Jones [ | 2002 | - | * | NA | * | - | - | - | - | - | – |
| Kabesch † [ | 2004 | * | * | NA | * | - | - | - | * | - | +/− |
| Kerkhof [ | 2010 | * | * | * | * | * | * | - | * | - | + |
| Lange [ | 2011 | * | * | NA | - | * | * | * | * | - | + |
| Lodrup Carlsen [ | 2010 | * | * | NA | * | * | * | - | * | * | + |
| O’Donnell [ | 2004 | * | * | NA | - | * | * | - | * | * | + |
| Reijmerink [ | 2010 | * | * | NA | * | - | - | - | * | - | +/− |
| Rothenbacher [ | 2005 | * | * | * | * | * | * | - | - | * | + |
| Simpson [ | 2006 | * | * | * | * | * | * | - | * | * | + |
| Snijders † [ | 2006 | * | * | * | * | * | * | - | - | * | + |
| Soferman [ | 2004 | - | * | NA | * | * | * | * | * | * | + |
S1: Representativeness of the exposed cohort, S2: Selection of non-exposed cohort, S3: Ascertainment of exposure, S4: Outcome of interest not present at start of study, C1a/C1b: Comparability of cohorts on the basis of the design or analysis, O1: Assessment of outcome, O2: Duration of follow-up, O3: Adequacy of follow up (*: criteria were met; -: criteria were not met); OQ: Overall quality (+ better than average quality, +/− average quality, – less than average quality); NA = not applicable; † cross-sectional study.
Quality scoring based on the Newcastle-Ottawa quality assessment scale: case control studies
| Bieli † [ | 2007 | - | * | * | - | * | * | * | * | * | + |
| Bjornvold [ | 2009 | */- | * | * | * | - | - | NA | NA | - | +/− |
| Choudhry [ | 2005 | - | - | * | - | * | * | - | * | - | +/− |
| Daley [ | 2009 | - | */- | * | - | - | - | NA | NA | - | +/− |
| Eder † [ | 2004 | - | * | * | - | * | * | * | * | - | +/− |
| Ege † [ | 2007 | - | * | * | - | * | * | * | * | * | + |
| Fageras Bottcher † [ | 2004 | * | - | - | - | * | * | * | * | - | +/− |
| Genuneit [ | 2009 | - | * | * | */- | * | - | NA | NA | - | +/− |
| Heinzmann [ | 2003 | * | * | * | - | - | - | NA | NA | - | +/− |
| Heinzmann [ | 2010 | * | - | * | - | - | - | NA | NA | - | +/− |
| Hoffjan [ | 2005 | - | - | - | * | - | - | NA | NA | - | – |
| Hussein [ | 2012 | * | * | - | * | - | - | NA | NA | - | +/− |
| Jackola [ | 2006 | * | - | * | * | * | - | NA | NA | - | +/− |
| Kabesch † [ | 2004 | - | * | * | - | - | - | NA | NA | - | +/− |
| Kormann§ [ | 2008 | * | * | * | * | * | - | NA | NA | - | + |
| Kurowski [ | 2011 | - | - | * | - | - | - | * | * | - | – |
| Marcos [ | 2010 | * | - | - | * | - | - | * | - | - | – |
| Miedema§ [ | 2012 | - | - | * | * | - | - | NA | NA | - | +/− |
| Moller-Larsen [ | 2008 | * | - | * | * | * | - | NA | NA | - | +/− |
| Perin [ | 2011 | * | - | - | * | - | - | NA | NA | - | +/− |
| Puthothu [ | 2006 | * | - | * | - | - | - | NA | NA | - | +/− |
| Schubert [ | 2006 | * | - | * | - | - | - | NA | NA | - | +/− |
| Sengler § [ | 2003 | - | * | * | * | * | - | NA | NA | - | +/− |
| Snijders † [ | 2006 | - | * | * | * | * | * | * | * | - | + |
| Sorensen § [ | 2009 | - | * | * | * | * | * | * | * | * | + |
| Tremblay [ | 2008 | - | */- | * | - | - | - | NA | NA | - | +/− |
| Yang [ | 2004 | - | - | * | * | * | * | NA | NA | - | +/− |
| Zhang [ | 2011 | * | * | * | * | * | * | * | * | - | + |
S1: Case definition; S2: Representativeness of the cases; S3: Selection of controls; S4: Definition of controls; C1a/C1b Comparability of cases and controls on the basis of the design or analysis; E1: Ascertainment of exposure; E2: Same method of ascertainment for cases and controls; E3: Non-response rate (*: criteria were met; -: criteria were not met); OQ: Overall quality (+: better than average quality, +/− average quality, – less than average quality); † cross-sectional study; § nested case control study; NA = not applicable.
Single nucleotide polymorphisms with association with asthma
| rs2569190 | C > T | 1 out of 15 (duplication [ | decreased asthma severity | [ | [ | |
| rs4914 | G > C | 1 out of 2 (duplication [ | decreased asthma incidence | [ | [ | |
| rs5743595 | T > C | 1 out of 1 | atopic asthma | [ | NA | |
| rs4833095 | A > G | 1 out of 1 | atopic asthma | [ | NA | |
| rs4696480 | A > T | 3 out of 5 (partial duplication [ | asthma/current asthma symptoms | [ | [ | |
| rs3804099 | T > C | 1 out of 6 (partial duplication [ | nonatopic asthma (inverse) | [ | [ | |
| rs3804100 | T > C | 1 out of 6 (partial duplication [ | allergic asthma (inverse) | [ | [ | |
| rs1898830 | A > G | 1 out of 4 | asthma | [ | [ | |
| rs5743708 | G > A | 1 out of 2 | asthma severity in atopic children | [ | [ | |
| rs2737190 | A > G | 1 out of 1 | (non-atopic) asthma | [ | NA | |
| rs4986790 | A > G | 3 out of 10 | asthma, atopic asthma and asthma severity in atopic children | [ | [ | |
| rs4986791 | C > T | 1 out of 4 | mild atopic asthma | [ | [ | |
| rs6531666 | T > C | 1 out of 1 | asthma | [ | NA | |
| rs5743789 | T > A | 1 out of 1 | atopic asthma | [ | NA | |
| rs5743798 | C > T | 1 out of 1 | asthma | [ | NA | |
| rs5743810 | C > T | 2 out of 5 | (atopic) asthma | [ | [ | |
| rs179008 | A > T | 1 out of 2 | asthma | [ | [ | |
| rs2407992 | G > C | 1 out of 1 | asthma | [ | NA | |
| rs187084 | T > C | 1 out of 3 | asthma | [ | [ | |
| rs4129009 | A > G | 1 out of 2 | atopic asthma inverse | [ | [ | |
| rs11096957 | A > C | 1 out of 3 | asthma | [ | [ |
Ref: reference, TLR: Toll-Like Receptor, NA: not applicable.